Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Stopped Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter
Conditions
Interventions
- DRUG: Moxetumomab Pasudotox
Sponsor
M.D. Anderson Cancer Center
Collaborators